[1]付大鵬.托瑞米芬聯合他莫昔芬應用于晚期乳腺癌的療效[J].醫學信息,2020,(04):139-140.[doi:10.3969/j.issn.1006-1959.2020.04.044]
 FU Da-peng.Analysis of the Efficacy of Toremifene Combined with Tamoxifen in Advanced Breast Cancer[J].Medical Information,2020,(04):139-140.[doi:10.3969/j.issn.1006-1959.2020.04.044]
點擊復制

托瑞米芬聯合他莫昔芬應用于晚期乳腺癌的療效()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2020年04期
頁碼:
139-140
欄目:
藥物與臨床
出版日期:
2020-02-15

文章信息/Info

Title:
Analysis of the Efficacy of Toremifene Combined with Tamoxifen in Advanced Breast Cancer
文章編號:
1006-1959(2020)04-0139-02
作者:
付大鵬
(解放軍聯勤保障部隊九六七醫院腫瘤科,遼寧 大連 116000)
Author(s):
FU Da-peng
(Department of Oncology,967 Hospital of PLA Joint Service,Dalian 116000,Liaoning,China)
關鍵詞:
托瑞米芬他莫昔芬晚期乳腺癌生存質量
Keywords:
ToremifeneTamoxifenAdvanced breast cancerQuality of life
分類號:
R737.9
DOI:
10.3969/j.issn.1006-1959.2020.04.044
文獻標志碼:
A
摘要:
目的 觀察晚期乳腺癌患者采用托瑞米芬聯合他莫昔芬的治療效果并分析患者生存質量。方法 選取2017年5月~2018年10月在我院診治的90例晚期乳腺癌患者為研究對象,采用隨機數字表法分為對照組和觀察組,各45例。對照組采用常規化療方案,觀察組在對照組基礎上應用托瑞米芬聯合他莫昔芬治療,比較兩組臨床總有效率、治療前后生存質量評分及毒副反應。 結果 觀察組總有效率為71.11%,高于對照組的51.11%(P<0.05);治療后兩組生存質量評分均高于治療前,且觀察組高于對照組(P<0.05);兩組毒副反應發生率比較,差異無統計學意義(P>0.05)。結論 晚期乳腺癌采用托瑞米芬聯合他莫昔芬治療,有助于提高治療療效,改善患者生存質量,且不會增加毒副反應,安全可靠。
Abstract:
Objective To observe the therapeutic effect of toremifene combined with tamoxifen on advanced breast cancer and analyze the quality of life of patients. Methods 90 patients with advanced breast cancer diagnosed and treated in our hospital from May 2017 to October 2018 were selected as the research subjects. They were divided into control group and observation group by using the random number table method, with 45 cases in each group. The control group was treated with conventional chemotherapy, and the observation group was treated with toremifene combined with tamoxifen on the basis of the control group. The total clinical effectiveness, quality of life scores before and after treatment, and toxic and side effects were compared between the two groups. Results The total effective rate in the observation group was 71.11%, which was higher than 51.11% in the control group(P<0.05). The quality of life scores of the two groups after treatment were higher than before the treatment, and the observation group was higher than the control group(P<0.05); Comparison of the incidence of toxic and side effects between the two groups,the difference was not statistically significant(P>0.05).Conclusion The treatment of toremifene combined with tamoxifen in advanced breast cancer is helpful to improve the curative effect and improve the quality of life of patients without increasing side effects. It is safe and reliable.

參考文獻/References:

[1]黎胤謀,李靖,周勇,等.他莫昔芬聯合依維莫司對ER陽性轉移性乳腺癌患者臨床應用分析[J].藥物生物技術,2018,25(2):10. [2]張保寧,陳萬青,張希,等.中國乳腺癌防控形勢面臨挑戰[J].中華腫瘤雜志,2016,38(10):798-800. [3]畢麗陽.MTDH、C-Met、TRAIL對乳腺癌化療敏感性的研究[D].河北醫科大學,2015. [4]王芬.表阿霉素聯合多西紫杉醇對三陰乳腺癌新輔助化療療效臨床觀察[J].醫學信息,2013,26(23):595. [5]宋強.托瑞米芬聯合他莫昔芬治療晚期乳腺癌的效果觀察及對肝功能和血脂的影響[J].齊齊哈爾醫學院學報,2017,38(15):1779-1781.

相似文獻/References:

[1]于 東.平消片為主組合方案治療乳腺增生癥臨床分析[J].醫學信息,2018,(08):136.[doi:10.3969/j.issn.1006-1959.2018.08.046]
 YU Dong.Clinical Analysis of the Combination of Pingxiao Tablets in the Treatment of Mammary Hyperplasia[J].Medical Information,2018,(04):136.[doi:10.3969/j.issn.1006-1959.2018.08.046]

更新日期/Last Update: 2020-02-15
中国足彩网竞彩 鼎牛配资官网 快三今天开奖全部结果 1分快3豹子规律技巧 美国的股票指数 牛的生肖是哪几个数 微信群二维码股票群 安徽11选5一定牛形态走势图 股票涨跌比怎么计算 唐山港股票行情 甘肃快3走势图~百度